ReviewCurrent opinion in allergy and clinical immunology2019
Recombinant allergens for immunotherapy: state of the art.
Review in Current opinion in allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Transient Expression and Immunogenicity Assessment of theVaccines · 2026Article
- Art an 3 as a candidate recombinant antigen for Artemisia pollen immunotherapy: comparative efficacy and mechanistic insights.Frontiers in medicine · 2026Article
- Insights into Isolation and Purification Strategies of Egg Allergens.Foods (Basel, Switzerland) · 2025Review
- Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites.The journal of allergy and clinical immunology. Global · 2025Article
- Advances in Allergen Immunotherapy and Safety.Vaccines · 2025Review
- Tissue-based skin prick test extracts from Atlantic salmon containing occupationally relevant allergens.Frontiers in allergy · 2025Article
- Polymerised mite allergoids with glutaraldehyde reduce proteolytic activity and enhance the stability of allergen mixtures: a proof of concept with grass mixtures.Frontiers in allergy · 2025Article
- Structural analysis of human IgE monoclonal antibody epitopes on dust mite allergen Der p 2.The Journal of allergy and clinical immunology · 2024Article
- Article
- Characterization of Hum j 6, a Major Allergen FromAllergy, asthma & immunology research · 2023Article
- A Cell-Free Protein Synthesis Platform to Produce a Clinically Relevant Allergen Panel.ACS synthetic biology · 2023Article
- World Experience in Immunization against Noncommunicable Diseases: Successes and Vectors for Further Development.Vaccines · 2023Article
- Component-Resolved Diagnosis Based on a Recombinant Variant of Mus m 1 Lipocalin Allergen.International journal of molecular sciences · 2023Article
- How the Immune System Responds to Allergy Immunotherapy.Biomedicines · 2022Review
- Mechanisms and biomarkers of successful allergen-specific immunotherapy.Asia Pacific allergy · 2022Review
- Review
- Review
- Allergen immunotherapy for food allergy: Evidence and outlook.Allergologie select · 2022Review
- Proteomics for Development of Food Allergy Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewMore than 30 years ago, the first molecular structures of allergens were elucidated and defined recombinant allergens became available. We review the state of the art regarding molecular AIT with the goal to understand why progress in this field has been slow, although there is huge potential for treatment and allergen-specific prevention. RECENT
findingsOn the basis of allergen structures, several AIT strategies have been developed and were advanced into clinical evaluation. In clinical AIT trials, promising results were obtained with recombinant and synthetic allergen derivatives inducing allergen-specific IgG antibodies, which interfered with allergen recognition by IgE whereas clinical efficacy could not yet be demonstrated for approaches targeting only allergen-specific T-cell responses. Available data suggest that molecular AIT strategies have many advantages over allergen extract-based AIT. SUMMARY: Clinical studies indicate that recombinant allergen-based AIT vaccines, which are superior to existing allergen extract-based AIT can be developed for respiratory, food and venom allergy. Allergen-specific preventive strategies based on recombinant allergen-based vaccine approaches and induction of T-cell tolerance are on the horizon and hold promise that allergy can be prevented. However, progress is limited by lack of resources needed for clinical studies, which are necessary for the development of these innovative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.